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Supposedly, thyrocyte-specific transcripts such as thyroglobulin (Tg) and thyroid-stimulating hormone receptor (TSH-R) were
proposed to be useful for the diagnosis of circulating tumour cells in patients suffering from differentiated thyroid carcinoma (DTC).
However, several research groups reported blood-borne Tg transcripts in healthy individuals. This study determines in particular the
origin of Tg mRNA in nucleated blood cells and analyses whether other tumour-associated sequences are absent in leukocytes, but
widely expressed in DTC. Therefore, expression analyses for Tg, TSH-R, cytokeratin 19 (CK 19), human telomerase reverse
transcriptase (hTERT) and oncofoetal fibronectin (onfFN) were carried out using cDNAs derived from (1) leukocyte fractions, (2) 18
follicular thyroid carcinomas (FTCs) and 48 papillary thyroid carcinomas (PTCs), and (3) leukocytes of two thyrocyte-depleted
individuals treated for C-cell carcinoma of the thyroid. Expression of onfFN was additionally analysed by semiquantitative RT–PCR
and by quantitative fluorescence-based real-time PCR. Tg and TSH-R expression was demonstrated not only in both athyroid
individuals, but in all leukocyte subgroups tested, while hTERT was absent in resting CD4
þ cells and only weakly expressed in the
CD8
þ group. CK 19 was notable in each leukocyte population except for resting CD14
þ, as well as for activated and resting
CD19
þ cells. All blood cell fractions proved negative for onfFN mRNA, whereas its presence in thyroid carcinoma was 78/98%
(FTC/PTC). Threshold cycle values were calculated at: porphobilinogen deaminase (PBGD) ¼25.9570.73 (FTC)/24.5575.43
(PTC) (P¼0.2878); onfFN¼25.4873.15 (FTC)/21.4473.44 (PTC) (*P¼0.0001). Finally, onfFN transcripts were detected in blood
samples of six out of nine patients with known DTC metastases, demonstrating a reliable assay functionality. We propose that real-
time RT–PCR of onfFN mRNA is superior to other markers in monitoring minimal residual disease in DTC with regard to both assay
sensitivity and specificity.
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Differentiated thyroid carcinoma (DTC) appears with an incidence
of approximately three out of 100000 and ranks 14th among the
major malignancies (Mazzaferri, 2000). In Europe and North
America, DTC is the most common endocrine malignancy
accounting for 1% of all tumours (Parker et al, 1997). Periodic
radioiodine scanning and serum thyroglobulin (Tg) measurement
are an integral part of the postoperative care. However, in about
13% of a population, interfering anti-Tg antibodies are present
(Pedersen et al, 2003) which may lead to a decreased Tg
immunoassay sensitivity (Ringel et al, 1998; Spencer et al, 1998).
Additionally, appropriate serum Tg measurement requires a TSH
stimulus achieved by rhTSH administration, which obviates the
need for long-term thyroid hormone withdrawal, leading to patient
morbidity due to symptomatic hypothyroidism. Both concepts
may cause tumour growth stimulation. Despite improved therapy
concepts and excellent prognosis, tumour relapse and metastases
do occur in 10% of patients (Mazzaferri, 2000). Thus, over the last
decade, many studies have attempted to improve DTC diagnosis
and patient follow-up using RT–PCR-based approaches in order
to track down circulating tumour cells (Ditkoff et al, 1996; Tallini
et al, 1998; Ringel et al, 1999; Wingo et al, 1999; Biscolla et al, 2000;
Bojunga et al, 2000; Weber et al, 2000; Bugalho et al, 2001; Takano
et al, 2001; Eszlinger et al, 2002; Span et al, 2003; Chinnappa et al,
2004; Elisei et al, 2004; Li et al, 2004).
Thyroglobulin mRNA was thought to originate from circulating
thyrocytes (Ringel et al, 1998), but other studies demonstrated
that physiological blood cells such as leukocytes are capable of
ectopic Tg mRNA transcription (Tallini et al, 1998; Bojunga et al,
2000; Bugalho et al, 2001; Takano et al, 2001; Eszlinger et al,
2002). To overcome these inherent limitations, one must consider
either cumbersome tumour cell enrichment from peripheral
blood or amplification of tumour-specific markers. However,
the exact origin of Tg transcripts in healthy volunteers remains
to be elucidated, and molecular approaches should integrate
sequences lacking the phenomenon of illegitimate transcription
in order to obtain signals specific for the respective malignant
cell.
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disease by blood assays, we decided to analyse promising
candidate transcripts, which have been discussed to be useful in
this context. For instance, cytokeratin 19 (CK 19) transcripts were
used in several studies as a molecular marker for tumour cell
detection (Datta et al, 1994; Burchill et al, 1995; Eltahir et al, 1998;
Trummer et al, 2000).
Furthermore, human telomerase reverse transcriptase (hTERT)
activity is associated with the majority of malignancies, and its
activity is absent in most benign tissues (Kim et al, 1994; de Kok
et al, 1999; Holt and Shay, 1999; Soria et al, 1999).
During tumorigenesis, fibronectin is alternatively spliced,
leading to isoforms such as the extracellular domains A/B (ED-
A/ED-B) and the III-connecting segment (III-cs) (Takano et al,
1997, 1999, 2000). These uniquely glycosylated isoforms are
predominantly expressed by foetal and neoplastic cells, and have
been designated oncofoetal fibronectin (onfFN) (Guller et al,
2003).
The overall purpose of this study is to analyse the expression
of Tg, thyroid-stimulating hormone receptor (TSH-R), CK 19,
hTERT, and onfFN transcripts in leukocytes, as well as in papillary
thyroid carcinomas (PTCs) and follicular thyroid carcinomas
(FTCs), respectively. Conspicuous mRNA sequence abundance in
DTC combined with unequivocal absence in leukocytes will serve
as a valuable diagnostic tool in cancer cell detection in the
peripheral blood, which is finally tested in a small group of
patients. Herein, we intentionally confine our focus to a selected
number of mRNA transcripts which can be useful in future
investigations of minimal residual disease in DTC with promising
clinical applications.
MATERIALS AND METHODS
Patient samples and blood
The local university ethics committee approved the study and
informed consent was obtained from all patients. Tissue samples
from patients suffering from FTC or PTC and from nonmalignant
thyroid glands were collected intraoperatively (FTC: n¼18, PTC:
n¼48, nonmalignant thyroid¼4), immediately snap-frozen in
liquid nitrogen, and stored at  801C. Of the FTC group, five
tumours represented oxyphilic thyroid carcinomas displaying
follicular architecture in more than 30% of the tumour (Musholt
et al, 2003). The diagnosis of all thyroid tissues was histopatho-
logically confirmed by an experienced pathologist prior to
analysis.
Commercial cDNA from different leukocyte fractions was used
as template for PCR (MTC Panel, Clontech, Heidelberg, Germany).
Two individuals with a history of medullary thyroid carcinoma
(MTC¼C-cell carcinoma) who additionally underwent radio-
iodine treatment following total thyroidectomy served as negative
controls for thyrocyte-depleted human blood. For onfFN expres-
sion analysis, blood samples from nine patients suffering from
either FTC or PTC metastatic disease and from eight healthy
control individuals were obtained. Mononuclear peripheral blood
cells were isolated from 5ml EDTA treated blood by Ficoll-Paque
s
(Nycomed, Oslo, Norway) density gradient centrifugation accord-
ing to the manufacturer’s protocol.
RNA extraction
Total RNA was extracted from tissue samples (20mg) by TRIzol
Reagent (Invitrogen, Karlsruhe, Germany), and genomic DNA
was eliminated by DNase I digest (Roche Diagnostics, Mannheim,
Germany) prior to RNA purification (RNeasy Kit, Qiagen, Hilden,
Germany). Peripheral blood-derived total RNA was isolated using
only the column-based RNeasy Kit (Qiagen). The total RNA
concentration was measured fluorometrically by use of RiboGreen
RNA Quantitation Kit (MoBiTec, Goettingen, Germany).
RT–PCR
Synthesis of cDNA was performed using either 4mg (tissue
samples) or 1mg (blood samples) of total RNA and 3ml oligo-
dT20 primer (25pmolml
 1) (MWG, Ebersberg, Germany). Follow-
ing incubation at 701C for 10min, a reaction mixture containing
4ml dNTPs (5mmolml
 1 of each dNTP) (Roche Diagnostics), 8ml
5  SuperScript II Buffer, 4ml DTT (0.1mmolml
 1) and 1ml
SuperScript II (200Uml
 1) (Invitrogen) was added and then
incubated for another 50/10min at 42/701C. The final volume of
this mixture was adjusted to 100ml using tRNA solution
(0.25mgml
 1) (Roche Diagnostics). For the PCR reaction, 9.5ml
of diethyl pyrocarbonate (DEPC)-treated double-distilled H2O
(ddH2O) was added to 2.5ml of cDNA. Amplification was
performed in 25ml total volume containing 2.5ml1 0   reaction
buffer (Promega, Mannheim, Germany), 1.5ml MgCl2
(25mmolml
 1), 0.4ml Taq polymerase (5Uml
 1) (Qiagen), 1ml
DTT (25mmolml
 1), 0.5ml of each oligonucleotide (50pmolml
 1)
(MWG), 1ml dNTPs (5mmolml
 1) (Roche Diagnostics) and 13ml
DEPC-ddH2O. After incubation at 941C for 3min, a touch-down
PCR programme was started at 941C/annealing temperature þ10/
721C for 30/45/60s with increments of 11C each for two cycles,
followed by 15 cycles at the specific annealing temperature and an
incubation at 701C for 5min. Reaction mixtures either lacking
template or containing RNA instead of cDNA served as negative
controls. The primer sequences and annealing temperatures used
in this study are listed in Table 1.
Polyacrylamide (15%) gel electrophoresis (PAGE)
Vertical PAGE was used for PCR product separation, and the
amplicons were visualised by silver staining as described
previously (Lichtinghagen et al, 1994). Resulting signals were
subdivided semiquantitatively in the categories high, intermediate,
low and none according to their band intensities.
Real-time PCR
Fluorescence resonance energy transfer (FRET) technology (Light-
Cycler, Roche Diagnostics) was used for real-time PCR analysis.
Expression of the low-abundance housekeeping gene PBGD served
Table 1 Synopsis of the oligonucleotides used
Sense primer Sequence Antisense primer Sequence T (1C) Bp
PBGD-for 50-attgctatgtccaccacagg-30 PBGD-rev 50-gcagggtttctagggtcttc-30 59 253
Tg-for 50-gccctctcttcagtggttgt-30 Tg-rev 50-ggaactccaaggaactggtc-30 59 405
TSH-R-for 50-tggggacagtgaagacatgg-30 TSH-R-rev 50-tgaagaaaccagccgtgttg-30 58 332
CK19-for 50-cagcattcacgggggctcc-30 CK19-rev 50-agcctgttccgtctcaaacttggt-30 64 421
hTERT-for 50-tgaacttgcggaagacagtg-30 hTERT-rev 50-gaggctgttcacctgcaaat-30 57 290
onfFN-for 50-tcttcatggaccagagatct-30 onfFN-rev 50-tatggtcttggcctatgcct-30 56 215
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mixture contained 2.5ml cDNA, 2ml PBGD/onfFN primer
(10pmolml
 1) (see Table 1), 2ml FRET probes (4pmolml
 1)
PBGD-FITC (tcctcctggcttcaccatcggagc-FITC), PBGD Cy5.5 (Cy5.5-
tctgcaagcgggaaaaccctcatg), onfFN-IIICS-FITC (ggtatgacactg
gaaatggtattcagct-FITC), onfFN-IIICS- Cy5.5 (Cy5.5-tggcacttctggt
cagcaacccag) (MWG), 2ml Fast Start DNA Master Hybridization
Mix, 3.2ml MgCl2 (25mmoll
 1) and 1ml DMSO (Roche Diagnos-
tics). The mixture was adjusted to 20ml using DEPC-ddH2O. For
denaturation, a temperature of 951C was maintained for 12min.
Amplification was performed at 95/59/721C for 15/12/10s (PBGD:
50 cycles, onfFN: 38 cycles, slope: 201Cs
 1) without colour
compensation mode. A standard calibration curve was constructed
for each sequence after cloning of positive controls as described
previously (Lichtinghagen et al, 1995), and the assay sensitivity
was determined using dilutions of the positive controls. Reaction
mixtures either lacking template or containing RNA served as
negative controls. In order to determine the real-time PCR
sensitivity, an absolute quantification of PBGD and onfFN target
sequences was calibrated by use of cloned cDNA serial dilutions.
The standard curve started at 10
8 (onfFN)/10
7 (PBGD) initial
cDNA copies. After measurement of the relative fluorescence
intensity (channel F3/F1) for each sample, a proportional baseline
adjustment for sample quantification was carried out by second
derivative maximum calculation, and the amount of each mRNA
transcript was expressed as a threshold cycle (ct) value.
Resulting ct values were used for statistical analysis to determine
the significant differences of onfFN and PBGD mRNA expression
in PTCs and FTCs, respectively, using a two-sample t-test.
RESULTS
Illegitimate transcription of supposedly thyrocyte-specific
transcripts in leukocytes
Activated and resting leukocyte subgroups were analysed for
transcription patterns of thyroid-associated mRNA products by
RT–PCR analysis. Whereas each leukocyte subgroup tested
positive for transcripts of Tg, TSH-R, and PBGD, divergent
expression profiles of hTERT, CK 19, and onfFN were observed
in CD subgroups.
hTERT transcripts were not detected within resting CD4
þ cells
and were found at only low levels within the CD8
þ population.
Resting CD14
þ cells as well as activated and resting CD19
þ cells
lacked CK 19 transcripts. All other fractions expressed CK 19. The
weakest expression was demonstrated in the CD8
þ group. No
leukocyte subgroup tested transcribed onfFN mRNA (Figure 1).
Nucleated peripheral blood cells of two patients without any
residual thyroid tissue following treatment for medullary thyroid
carcinoma were positive for Tg mRNA (Figure 2).
Tissue samples
Total RNA was extracted from 48 PTCs, 13 FTCs, and five
oxyphilic follicular thyroid carcinomas (oxyFTCs) – often
synonymously designated as Huerthle cell carcinomas – and four
nonmalignant thyroid tissue samples. RT–PCR for PBGD, hTERT,
onfFN, and CK 19 was performed and analysed by PAGE. As
expected, PBGD expression was detectable in all tumours
examined. Half of the FTC samples and 29% of the PTC tumours
were negative for hTERT. High levels of hTERT were observed in
34/33% (FTC/PTC), intermediate levels in 6/31%, and a low level of
expression occurred in 11% of each tumour group. Detectable
levels of onfFN transcripts were present in 78/98% (FTC/PTC). The
FTC samples revealed high expression in 11% of the tumours,
whereas a high expression of onfFN was observed in 60% of PTCs.
Intermediate and low levels (17%) of onfFN were detected in one-
half of the FTC samples. A quarter of all PTC tumours displayed
intermediate and low (13%) onfFN signals. All tumour tissues
transcribed CK 19 at a relatively high level (66% for FTCs; 88% for
PTCs). Intermediate and low levels were measured in 17% of FTCs
PBGD 
TSH-R 
Tg 
hTERT 
CK 19 
onfFN 
CD14+
r CD4+
r CD4+
a CD8+
r CD8+
a CD19+
r CD19+
a
Figure 1 Tg, TSH-R, the low-abundance house-keeping gene PBGD,
hTERT, CK 19, and onfFN mRNA transcripts were PCR-amplified using
cDNA from different leukocyte subgroups. Amplicons were visualised by
PAGE, followed by silver staining. The subscripts (r and a) indicate resting
or activated status, respectively, for each subgroup.
MTC patient 2  MTC patient 1 
200 bp
300 bp 
400 bp 
M 
500 bp 
12 3   4 
Figure 2 In the study of minimal residual disease in DTC, two thyrocyte-
depleted individuals – suffering from medullary thyroid carcinoma and
treated with thyroidectomy as well as with radio-iodine therapy – served as
negative controls (MTC patients 1 and 2). RT–PCR amplification for Tg
(lanes 1þ3, product size: 405bp) and PBGD (lanes 2þ4, product size:
253bp) transcripts was carried out following harvest of nucleated
peripheral blood cells by density gradient centrifugation (M¼100bp
DNA ladder). A notable expression of the supposedly thyrocyte-specific Tg
is shown (PAGE, silver staining).
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sand 6% of PTCs examined (Figure 3). There was no specific
expression pattern detectable discerning oxyFTCs from FTCs
without oxyphilic histomorphology. Nonmalignant thyroid tissue
samples were only analysed for onfFN mRNA expression and were
found to be negative.
Quantification
In order to determine the real-time PCR sensitivity, an absolute
quantification of PBGD and onfFN target sequences was calibrated
by use of cloned cDNA serial dilutions. Sensitivity of the assay
was determined to be 10
3 (onfFN)/10
4 (PBGD) cDNA molecules
per reaction. The correlation coefficient was R¼0.99 for onfFN as
well as for PBGD.
In order to determine the inter-assay precision, two samples of
both onfFN and PBGD standards of different concentrations were
cycled eight times in a row. Amplification of 10
6 cDNA copies
(onfFN and PBGD) revealed a mean ct value of 19.75 (s.d.70.16,
CV¼0.8%) for onfFN, and 22.08 (s.d.70.56, CV¼9.2%) for
PBGD, respectively. Amplification of a lower concentration
(onfFN: 10
3, PBGD: 10
5) proved a mean ct value of 25.84
(s.d.72.39, CV¼9.2%) for onfFN and 24.9 (s.d.70.22,
CV¼0.9%) for PBGD.
PBGD and onfFN transcripts of 18 FTC and 48 PTC samples
were then quantified by real-time PCR using the calibration curve
made of diluted cloned controls. Calculation was performed by
second derivative maximum analysis and the quantity of each
transcript was expressed as ct values. A mean PBGD ct was
observed at 25.9570.73 for FTC samples and 24.5575.43 for PTC
tumours, demonstrating no significant difference (P¼0.2878).
onfFN ct were calculated at 25.4873.15 and 21.4473.44 for FTC
and PTC samples, respectively. The expression difference between
both tumour groups was significant (*P¼0.0001) (Figure 4).
Peripheral blood from patients with confirmed FTC or PTC
metastases tested positive for onfFN mRNA expression in six out
of nine cases using the established assay. The signal was
significantly (*P¼0.015) higher in patients (mean: 1.7 10
4, s.d.:
8.6 10
3 (arbitrary units)) compared to controls (n¼8) (mean:
7.1 10
3, s.d.: 2.0 10
3 (arbitrary units)). A cutoff value
(3 s.d.þmean¼1.3 10
4 (arbitrary units)) was applied to
identify positive samples (Figure 5). The results were confirmed
three times with a high reproducibility.
Using a thyroid carcinoma cell line dilution model, we found
one tumour cell in 10
6 mononuclear cells (data not shown).
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Figure 3 Tissue samples of 18 FTCs and 48 PTCs were subjected to
RT–PCR-based semiquantitative expression analysis for PBGD, hTERT,
onfFN, and CK 19, respectively. Following PAGE and silver staining, band
intensities were estimated and illustrated.
Threshold cycle (ct) values
0
5
10
15
20
25
30
35
c
t
onfFN PBGD
PTC  FTC 
P = 0.2878 
*P = 0.0001 
Figure 4 Results of a real-time PCR quantification of PBGD and onfFN
transcripts performed on cDNA from 18 FTC and 48 PTC samples are
given using ct values after second derivative maximum analysis.
8 9 n =
Controls Patients
o
n
f
F
N
 
m
R
N
A
 
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
4.0E+04
3.0E+04
2.0E+04
1.0E+04
0
Cutoff 
*P = 0.015 
Figure 5 Quantitative real-time PCR data are shown in a box plot graph.
Based on an unspecific background signal obtained in healthy controls
(n¼8), we calculated a cutoff value (3 s.d.þmean). onfFN transcripts
were detected in the peripheral blood in 67% of patients (n¼9) suffering
from DTC metastatic disease. Expression rates of both groups are
presented in arbitrary units based on copy numbers of a recombinant
onfFN standard, leading to a better inter-assay precision in daily routine
diagnostic.
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sDISCUSSION
In the recent past years, a considerable number of papers reporting
tissue-specific or cell-specific gene expression analyses for diagnosis
of minimal residual disease in DTCs following total thyroidectomy
were published. Some laboratories focused on Tg mRNA as a
thyroid-associated gene product in detecting DTC cells in peripheral
blood; however, Tg expression analysis produced ambiguous and
diverse results (Ditkoff et al, 1996; Tallini et al, 1998; Ringel et al,
1999; Wingo et al, 1999; Bojunga et al, 2000; Bugalho et al,2 0 0 1 ;
Takano et al, 2001; Eszlinger et al, 2002; Grammatopoulos et al,
2003). A recently published review concluded that Tg mRNA
measurement is an invalid approach in the postoperative care of
patients with DTC due to illegitimate expression of this marker in
peripheral blood cells, although RT–PCR concepts in general are
worthy of further investigations (Verburg et al, 2004). However, two
other studies demonstrated results opposite to the conclusions
drawn in this review, and reported a high specificity of Tg or TSH-R
mRNA for thyroid cancer, hence promoting their application in
DTC detection (Chinnappa et al,2 0 0 4 ;L iet al, 2004). Therefore, the
experimental usefulness of Tg transcripts and the potential clinical
relevance of this marker are still under debate.
A somewhat different method capable of detecting circulating
thyroid carcinoma cells was first described by Ditkoff et al (1996).
In their study, Tg mRNA was present in the peripheral blood of
all patients with metastatic cancer, but absent in controls and in
almost all individuals in disease remission. Investigators subse-
quently interpreted their observations to be correlated with
extrathyroidal disease. Others reported a previously Tg mRNA
negative control group revealing positive results following
extended PCR amplification. The same was true for 10 human
cell lines tested (Tallini et al, 1998). Healthy individuals who
revealed circulating Tg mRNA transcripts in the peripheral blood
were also described by Ringel et al (1998) using the RT–PCR
technique. They interpreted their findings with a putative pool of
circulating normal thyrocytes which produced Tg mRNA.
Refuting, we studied the peripheral blood of two patients lacking
any residual thyroid tissue whatsoever because they underwent not
only thyroidectomy for medullary thyroid carcinoma (originating
from intrathyroidal C-cells and not from thyrocytes) but also – as
an unusual additional treatment – radio-iodine therapy after
surgery. The leukocyte fraction of these two individuals separated
by density gradient centrifugation notedly revealed Tg mRNA
expression (Figure 2). In addition, we have clearly demonstrated an
ectopic transcription of Tg and TSH-R mRNA in all nucleated cell
fractions of the peripheral blood using a highly sensitive two-step
RT–PCR method (Figure 1). These findings strongly support the
hypothesis that lymphocytes, monocytes and granulocytes express
markers illegitimately, which were reported to be thyrocyte-
specific. This phenomenon leads to a significant thyrocyte-
independent PCR background signal, which interferes with assays
using Tg and TSH-R mRNA. Based on these data, one can conclude
that the hypothesis of circulating thyrocytes in healthy individuals
as the source of peripheral Tg transcripts proposed by Ringel et al
is improbable (Bojunga et al, 2000; Bugalho et al, 2001; Takano
et al, 2001; Eszlinger et al, 2002). Experimental trials or future
clinical applications dealing with Tg or TSH-R mRNA transcripts
should be wary of false-positive results. Chelly et al (1989) reported
that illegitimate transcription corresponds with a low expression
level of spliced transcripts from specific genes in cells that are
nonspecific for these transcripts. Due to identical promoter
elements in specific and nonspecific cells, illegitimate or ectopic
transcription is likely to be a result of a low promoter activity
leading to nontranslated transcripts. The significance and wide-
spread appearance of this phenomenon still need to be elucidated.
A general tolerance of low-level promoter activity might be
energetically advantageous for cellular metabolism rather than
resting at complete promoter quiescence (Chelly et al, 1991).
Concluding, in detection of minimal residual disease in DTC,
either time-consuming, sophisticated carcinoma cell harvesting or
detection of circulating cancer cell via nonillegitimately tran-
scribed sequences is feasible. In our opinion, the latter approach is
preferable because it is more sensitive, specific, cost-effective and
subject to routine laboratory automation.
As long as no thyrocyte-specific master genes are available, the
amplification of minor genes not primarily involved in thyroid
function but abnormally expressed in certain stages of tumori-
genesis – due to gene deregulation and disturbances in molecular
networks – is currently the only approach for detection of minimal
residual disease in thyroid carcinoma.
In order to establish a single marker-based tumour cell detection
assay, a consistently high expression of the chosen target mRNA
sequence by the malignant tissue is required. Thus, we studied
expression rates of the potential target sequences hTERT, CK 19,
and onfFN in PTCs, FTCs, nonmalignant thyroid tissue, as well
as in leukocyte subgroups. Our results demonstrate the complete
absence of onfFN transcripts in each CD population associated with
a high expression rate in DTC samples (Figures 1 and 3), suggesting
that the onfFN transcript is a useful target sequence for thyroid
carcinoma cell detection within the peripheral blood. Additionally,
a significant difference in onfFN mRNA expression between PTCs
and FTCs was shown (Figure 4), whereas the nonmalignant thyroid
tissue samples lacked onfFN transcripts (data not shown). In
further support of our results, Giannini et al (2003) assessed onfFN
and galectin-3 mRNA in thyroid malignancies, and reported onfFN
mRNA transcripts in almost 98% of PTCs.
Importantly, the analysis of peripheral blood from patients with
known DTC metastatic disease revealed an onfFN mRNA
expression in six out of nine patients identified by a well-defined
cutoff value (Figure 5). This finding indicates the technical
feasibility, reliability and potential clinical utility of this approach.
In summary, we have developed and optimised a specific,
sensitive real-time RT–PCR assay using FRET technology in order
to quantify absolute amounts of onfFN templates. A high
expression rate of onfFN transcripts in DTCs was demonstrated,
while onfFN mRNA was not found to be illegitimately transcribed
by peripheral blood cells, but patients with DTC metastatic disease
could be identified. These results may lead to a specific tool for
monitoring micrometastases in the context of minimal residual
disease or for assessing tumour response to therapy. The assay of
onfFN-specific transcripts is a promising approach and worthy of
further assessment in clinical trials.
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